Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04656067
Other study ID # DR,ABDELAZIM SOBHI
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date April 1, 2020
Est. completion date November 10, 2020

Study information

Verified date February 2021
Source Egymedicalpedia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Comparative Study Between Oxytocin Versus Tranexamic Acid and Ethamsylate, Pre-operative Administration.


Description:

Caesarean Delivery commonly referred to as caesarean section and occasionally caesarean birth is defined as the delivery of a foetus(es) through surgical incisions made through the anterior abdominal wall (technically referred to as laparotomy) and the anterior uterine wall (technically denoted to as hysterotomy). Obstetric Hemorrhage (Intra operative OR post operative bleeding)is still the major cause of maternal morbidity and mortality worldwide contributing to nearly 25% of direct maternal deaths. And accounts for 50% of maternal mortality in low-income countries. So many Strategies reducing the intraoperative blood loss or post operative blood loss could be helpful in decreasing the risks of blood transfusion and the postoperative maternal morbidity. So these Medications are such as Oxytocin, Carbetocin, Misoprostol, Prostaglandin F2 alpha, methylergonovine, Tranexamic acid and Etamsylate . have been tried before to control bleeding during and after Cesarean Section.


Recruitment information / eligibility

Status Completed
Enrollment 230
Est. completion date November 10, 2020
Est. primary completion date October 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 40 Years
Eligibility Inclusion Criteria: 1. Pregnant females admitted for elective Cesarean Section. 2. Gestational age (38 to 41 weeks). 3. Age of the participants: 20 to 40 years. 4. Body Mass Index (18.5 - 29.9). 5. Singleton living fetus. 6. No medical disorders. 7. Informed written consent from the candidates. Exclusion criteria: 1. - Medical and surgical disorders as thyroid dysfunction, which was excluded by routine thyroid function test (free T3, free T4, and thyroid-stimulating hormone(TSH), all of them should be within normal limits). 2. -Bleeding tendency, was excluded by platelet count, coagulation time, bleeding time, prothrombin time, partial thromboplastin time, and thrombin time (all should be within normal). 3. -Acute and chronic liver or kidney diseases; blood disorders, such as anemia. 4. -Allergy to Tranexamic acid or any drug used. 5. -Risk factors for PPH, such as polyhydramnios, fetal macrosomia, antepartum hemorrhage. 6. - Abnormal placentae such as placenta previa and placental abruption. 7. -Pregnancy complications such as severe pre-eclampsia, Gestational HTN, Gestational DM, and multi Fetal pregnancies, those requiring blood transfusion. 8. - Patients who refused spinal anesthesia.

Study Design


Intervention

Drug:
Oxytocin ,Tranexamic acid and Ethamsylate
Is to compare blood loss during elective cesarean section intraoperative and postoperative in cases receiving Oxytocin versus Tranexamic acid and Ethamsylate

Locations

Country Name City State
Egypt Sayed Galal Hospital and Shoubra General Hospital Cairo

Sponsors (1)

Lead Sponsor Collaborator
Egymedicalpedia

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intraoperative and Post operative bleeding(defined as blood loss =500 cc) Outcome of the study will be measured in terms of assessment of Hemoglobin level and Hematocrit level pre and post operatively. First 2 hours after C-Section
Secondary Sever PPH as bleeding is >1000 cc Outcome of the study will be measured in terms of assessment of Hemoglobin level and Hematocrit level post operatively. first 24 hours after C-Section
See also
  Status Clinical Trial Phase
Completed NCT04114253 - QStat in Liver Transplant
Recruiting NCT05077124 - Safe and Timely Antithrombotic Removal (STAR) Registry
Active, not recruiting NCT03651154 - Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections N/A
Recruiting NCT04519593 - ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma N/A
Completed NCT02043132 - Tranexamic Acid in Reverse Total Shoulder Arthroplasty Phase 2/Phase 3
Withdrawn NCT00861367 - Prospective Double-blind Study for the Use of Aspirin During Transurethral Surgery of the Bladder or the Prostate N/A
Terminated NCT03246919 - Ideal Time of Oxytocin Infusion During Cesarean Section Phase 4
Completed NCT04443920 - Tranexamic Acid for Total Knee Arthroscopy Phase 4
Withdrawn NCT04933253 - Mediastinal Temperature and Post-operative Bleeding N/A
Recruiting NCT02938962 - Intravenous vs. Topical Tranexamic Acid in Revision THA (VITALITY-X) Phase 4
Recruiting NCT02130752 - Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery N/A
Recruiting NCT05164809 - Effect of Electrosurgery on Blood Loss and Intraoperative Transfusions in Musculoskeletal Tumor Surgery
Not yet recruiting NCT04574128 - Retransfusion or Not of Cardiotomy Blood N/A
Completed NCT02911831 - IV Tranexamic Acid Prior to Hysterectomy Early Phase 1
Completed NCT02740374 - Evaluation of Thromboelastometry (ROTEM) During Spinal Surgery N/A
Enrolling by invitation NCT05474027 - Reducing Hypotensive Anesthesia Use With TXA During Orthognathic Surgery Phase 4
Completed NCT05391607 - Comparison Between Hyperoncotic and Isooncotic Albumin to Support Blood Loss Replacement Phase 4
Completed NCT03152461 - Evaluation of the Clinical Performance of the Quantra System With the Quantra Surgical Cartridge
Recruiting NCT02441751 - Intraoperative Volume Management and QT Interval
Completed NCT01053169 - Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study) N/A